{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:26Z","timestamp":1792782686654,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health \/ National Cancer Institute","award":["R01CA211887"],"award-info":[{"award-number":["R01CA211887"]}]},{"name":"National Institutes of Health \/ National Cancer Institute","award":["R01CA189947"],"award-info":[{"award-number":["R01CA189947"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00520-019-04987-8","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T13:03:01Z","timestamp":1564491781000},"page":"3729-3737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview"],"prefix":"10.1007","volume":"27","author":[{"given":"Alexandre","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Pon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharkia","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"D\u2019Olimpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Gobbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kord","family":"Kober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwaria","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas S.","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-5645","authenticated-orcid":false,"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"issue":"7","key":"4987_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00520-013-1766-y","volume":"21","author":"JS Gewandter","year":"2013","unstructured":"Gewandter JS, Fan L, Magnuson A et al (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21(7):2059\u20132066","journal-title":"Support Care Cancer"},{"issue":"2","key":"4987_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11764-017-0662-8","volume":"12","author":"C Miaskowski","year":"2018","unstructured":"Miaskowski C, Mastick J, Paul SM et al (2018) Impact of chemotherapy-induced neurotoxicities on adult cancer survivors\u2019 symptom burden and quality of life. J Cancer Surviv 12(2):234\u2013245","journal-title":"J Cancer Surviv"},{"issue":"12","key":"4987_CR3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 155(12):2461\u20132470","journal-title":"Pain."},{"key":"4987_CR4","doi-asserted-by":"publisher","first-page":"e01312","DOI":"10.1002\/brb3.1312","volume":"9","author":"A Molassiotis","year":"2019","unstructured":"Molassiotis A, Cheng HL, Leung KT et al (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 9:e01312","journal-title":"Brain Behav"},{"issue":"2","key":"4987_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ygyno.2018.12.002","volume":"152","author":"HW Bulls","year":"2019","unstructured":"Bulls HW, Hoogland AI, Kennedy B et al (2019) A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol 152(2):310\u2013315","journal-title":"Gynecol Oncol"},{"issue":"25","key":"4987_CR6","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","volume":"34","author":"DL Hershman","year":"2016","unstructured":"Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65\u00a0years or older in southwest oncology group clinical trials. J Clin Oncol 34(25):3014\u20133022","journal-title":"J Clin Oncol"},{"issue":"4","key":"4987_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clcc.2017.03.013","volume":"16","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Fischer HD, Fung K et al (2017) Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer 16(4):397\u2013404 e391","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"4987_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00520-005-0868-6","volume":"14","author":"AA Argyriou","year":"2006","unstructured":"Argyriou AA, Polychronopoulos P, Koutras A et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223\u2013229","journal-title":"Support Care Cancer"},{"issue":"2","key":"4987_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MJT.0b013e3181a3e50b","volume":"17","author":"Z Nurgalieva","year":"2010","unstructured":"Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL (2010) Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 17(2):148\u2013158","journal-title":"Am J Ther"},{"issue":"6","key":"4987_CR10","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00520-017-3571-5","volume":"25","author":"E Cox-Martin","year":"2017","unstructured":"Cox-Martin E, Trahan LH, Cox MG, Dougherty PM, Lai EA, Novy DM (2017) Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer 25(6):1873\u20131879","journal-title":"Support Care Cancer"},{"issue":"22","key":"4987_CR11","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","volume":"21","author":"BP Schneider","year":"2015","unstructured":"Schneider BP, Li L, Radovich M et al (2015) Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21(22):5082\u20135091","journal-title":"Clin Cancer Res"},{"key":"4987_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 10:174","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"4987_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12876-016-0561-x","volume":"17","author":"Y Cao","year":"2017","unstructured":"Cao Y, Zhang G, Wang P et al (2017) Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol 17(1):2","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"4987_CR14","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1007\/s13277-014-1746-y","volume":"35","author":"X Zhang","year":"2014","unstructured":"Zhang X, Jiang LP, Yin Y, Wang YD (2014) XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumor Biol 35(6):5637\u20135645","journal-title":"Tumor Biol"},{"issue":"5","key":"4987_CR15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1055-9965.801.13.5","volume":"13","author":"S Savas","year":"2004","unstructured":"Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomark Prev 13(5):801\u2013807","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"4987_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0092-8674(01)00195-7","volume":"104","author":"CJ Whitehouse","year":"2001","unstructured":"Whitehouse CJ, Taylor RM, Thistlethwaite A et al (2001) XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 104(1):107\u2013117","journal-title":"Cell."},{"issue":"1","key":"4987_CR17","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.1038\/s41598-017-08257-7","volume":"7","author":"X Song","year":"2017","unstructured":"Song X, Wang S, Hong X et al (2017) Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. Sci Rep 7(1):11785","journal-title":"Sci Rep"},{"issue":"2","key":"4987_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdt546","volume":"25","author":"A Custodio","year":"2014","unstructured":"Custodio A, Moreno-Rubio J, Aparicio J et al (2014) Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25(2):398\u2013403","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"4987_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jns.2014.12.041","volume":"349","author":"C Johnson","year":"2015","unstructured":"Johnson C, Pankratz VS, Velazquez AI et al (2015) Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 349(1\u20132):124\u2013128","journal-title":"J Neurol Sci"},{"key":"4987_CR20","unstructured":"Hertz D, Kidwell K, K. V, D. S, NL. H. (2017) Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy. San Antonio Breast Cancer Symposium. 2017."},{"issue":"4","key":"4987_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cam4.625","volume":"5","author":"GK Boora","year":"2016","unstructured":"Boora GK, Kanwar R, Kulkarni AA et al (2016) Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med 5(4):631\u2013639","journal-title":"Cancer Med"},{"issue":"9","key":"4987_CR22","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-13-3232","volume":"20","author":"JE Abraham","year":"2014","unstructured":"Abraham JE, Guo Q, Dorling L et al (2014) Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res 20(9):2466\u20132475","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4987_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/bjc.2016.326","volume":"115","author":"SW Lam","year":"2016","unstructured":"Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E (2016) Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br J Cancer 115(11):1335\u20131342","journal-title":"Br J Cancer"},{"issue":"1\u20132","key":"4987_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2015.06.056","volume":"357","author":"GK Boora","year":"2015","unstructured":"Boora GK, Kulkarni AA, Kanwar R et al (2015) Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 357(1\u20132):35\u201340","journal-title":"J Neurol Sci"},{"issue":"4","key":"4987_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3109\/0284186X.2014.969846","volume":"54","author":"L Eckhoff","year":"2015","unstructured":"Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 54(4):530\u2013537","journal-title":"Acta Oncol"},{"key":"4987_CR26","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.2147\/OTT.S106574","volume":"9","author":"T Kus","year":"2016","unstructured":"Kus T, Aktas G, Kalender ME et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and Ther 9:5073\u20135080","journal-title":"OncoTargets and Ther"},{"issue":"69","key":"4987_CR27","doi-asserted-by":"crossref","first-page":"113531","DOI":"10.18632\/oncotarget.22697","volume":"8","author":"AGJ van Rossum","year":"2017","unstructured":"van Rossum AGJ, Kok M, McCool D et al (2017) Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget. 8(69):113531\u2013113542","journal-title":"Oncotarget."},{"issue":"1","key":"4987_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-014-2910-1","volume":"145","author":"DL Hertz","year":"2014","unstructured":"Hertz DL, Roy S, Jack J et al (2014) Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat 145(1):245\u2013254","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4987_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt.506","volume":"101","author":"W Stock","year":"2017","unstructured":"Stock W, Diouf B, Crews KR et al (2017) An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 101(3):391\u2013395","journal-title":"Clin Pharmacol Ther"},{"key":"4987_CR30","doi-asserted-by":"crossref","unstructured":"Wright GEB, Amstutz U, Drogemoller BI, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2018;105(2):402-410","DOI":"10.1002\/cpt.1179"},{"issue":"2","key":"4987_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","volume":"26","author":"A Gutierrez-Camino","year":"2016","unstructured":"Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E et al (2016) Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics 26(2):100\u2013102","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"4987_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/FPC.0000000000000345","volume":"28","author":"NK Zgheib","year":"2018","unstructured":"Zgheib NK, Ghanem KM, Tamim H et al (2018) Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics 28(8):189\u2013195","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"4987_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.116.235283","volume":"359","author":"MR Kelley","year":"2016","unstructured":"Kelley MR, Wikel JH, Guo C et al (2016) Identification and characterization of new chemical entities targeting apurinic\/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther 359(2):300\u2013309","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"4987_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3109\/0284186X.2014.985388","volume":"54","author":"AA Kulkarni","year":"2015","unstructured":"Kulkarni AA, Boora G, Kanwar R et al (2015) RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1. Acta Oncol 54(8):1227\u20131229","journal-title":"Acta Oncol"},{"issue":"12","key":"4987_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1440-1754.2011.02103.x","volume":"47","author":"AS Moore","year":"2011","unstructured":"Moore AS, Norris R, Price G et al (2011) Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 47(12):875\u2013882","journal-title":"J Paediatr Child Health"},{"key":"4987_CR36","doi-asserted-by":"crossref","unstructured":"Skiles JL, Chiang C, Li CH, et al. (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer 65(3).","DOI":"10.1002\/pbc.26854"},{"issue":"5","key":"4987_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440","journal-title":"Lancet Oncol"},{"issue":"3","key":"4987_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/pbc.22845","volume":"56","author":"A Egbelakin","year":"2011","unstructured":"Egbelakin A, Ferguson MJ, MacGill EA et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361\u2013367","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"4987_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/hon.2391","volume":"36","author":"C Campo","year":"2018","unstructured":"Campo C, da Silva Filho MI, Weinhold N et al (2018) Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients. Hematol Oncol 36(1):232\u2013237","journal-title":"Hematol Oncol"},{"issue":"6","key":"4987_CR40","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00280-011-1745-2","volume":"68","author":"R Guilhaumou","year":"2011","unstructured":"Guilhaumou R, Solas C, Bourgarel-Rey V et al (2011) Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68(6):1633\u20131638","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4987_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","volume":"21","author":"R Favis","year":"2011","unstructured":"Favis R, Sun Y, van de Velde H et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21(3):121\u2013129","journal-title":"Pharmacogenet Genomics"},{"issue":"17","key":"4987_CR42","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1158\/1078-0432.CCR-15-3163","volume":"22","author":"F Magrangeas","year":"2016","unstructured":"Magrangeas F, Kuiper R, Avet-Loiseau H et al (2016) A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in european patients with multiple myeloma. Clin Cancer Res 22(17):4350\u20134355","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4987_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","volume":"29","author":"DC Johnson","year":"2011","unstructured":"Johnson DC, Corthals SL, Walker BA et al (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29(7):797\u2013804","journal-title":"J Clin Oncol"},{"issue":"9","key":"4987_CR44","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.leukres.2011.02.009","volume":"35","author":"MT Cibeira","year":"2011","unstructured":"Cibeira MT, de Larrea CF, Navarro A et al (2011) Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res 35(9):1178\u20131183","journal-title":"Leuk Res"},{"issue":"5","key":"4987_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","volume":"10","author":"RW Gregg","year":"1992","unstructured":"Gregg RW, Molepo JM, Monpetit VJ et al (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10(5):795\u2013803","journal-title":"J Clin Oncol"},{"issue":"6","key":"4987_CR46","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.2001.19.6.1629","volume":"19","author":"R de Wit","year":"2001","unstructured":"de Wit R, Roberts JT, Wilkinson PM et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19(6):1629\u20131640","journal-title":"J Clin Oncol"},{"issue":"7","key":"4987_CR47","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.1991.9.7.1163","volume":"9","author":"CR Nichols","year":"1991","unstructured":"Nichols CR, Williams SD, Loehrer PJ et al (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9(7):1163\u20131172","journal-title":"J Clin Oncol"},{"issue":"27","key":"4987_CR48","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/pnas.1305321110","volume":"110","author":"JA Sprowl","year":"2013","unstructured":"Sprowl JA, Ciarimboli G, Lancaster CS et al (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110(27):11199\u201311204","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 7","key":"4987_CR49","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1002\/jcph.706","volume":"56","author":"A Hucke","year":"2016","unstructured":"Hucke A, Ciarimboli G (2016) The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol 56(Suppl 7):S157\u2013S172","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4987_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00280-014-2525-6","volume":"74","author":"Q Chalret du Rieu","year":"2014","unstructured":"Chalret du Rieu Q, White-Koning M, Picaud L et al (2014) Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol 74(3):571\u2013582","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4987_CR51","first-page":"2301","volume":"22","author":"SS Shord","year":"2002","unstructured":"Shord SS, Bernard SA, Lindley C et al (2002) Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res 22(4):2301\u20132309","journal-title":"Anticancer Res"},{"issue":"1","key":"4987_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s10147-009-0015-3","volume":"15","author":"K Ishibashi","year":"2010","unstructured":"Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15(1):82\u201387","journal-title":"Int J Clin Oncol"},{"key":"4987_CR53","first-page":"CD005228","volume":"3","author":"JW Albers","year":"2014","unstructured":"Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 3:CD005228","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4987_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/2347-5625.170977","volume":"3","author":"J Schloss","year":"2016","unstructured":"Schloss J, Colosimo M, Vitetta L (2016) New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs 3(1):73\u201385","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"10","key":"4987_CR55","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ctrv.2015.10.010","volume":"41","author":"CN Frederiks","year":"2015","unstructured":"Frederiks CN, Lam SW, Guchelaar HJ, Boven E (2015) Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev 41(10):935\u2013950","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"4987_CR56","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","volume":"11","author":"S Mielke","year":"2005","unstructured":"Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843\u20134850","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4987_CR57","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdw290","volume":"27","author":"M Joerger","year":"2016","unstructured":"Joerger M, von Pawel J, Kraff S et al (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 27(10):1895\u20131902","journal-title":"Ann Oncol"},{"issue":"3","key":"4987_CR58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/cpt.674","volume":"102","author":"K Agergaard","year":"2017","unstructured":"Agergaard K, Mau-Sorensen M, Stage TB et al (2017) Clopidogrel-paclitaxel drug-drug interaction: a pharmacoepidemiologic study. Clin Pharmacol Ther 102(3):547\u2013553","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4987_CR59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00540-017-2362-y","volume":"31","author":"M Matsuo","year":"2017","unstructured":"Matsuo M, Ito H, Takemura Y et al (2017) Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. J Anesth 31(4):631\u2013635","journal-title":"J Anesth"},{"issue":"3","key":"4987_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/35058515","volume":"2","author":"DG Wilkinson","year":"2001","unstructured":"Wilkinson DG (2001) Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2(3):155\u2013164","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"4987_CR61","first-page":"336","volume":"14","author":"A Chhibber","year":"2014","unstructured":"Chhibber A, Mefford J, Stahl EA et al (2014) Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharm J 14(4):336\u2013342","journal-title":"Pharm J"},{"key":"4987_CR62","doi-asserted-by":"crossref","unstructured":"Schneider BP, Li L, Miller K, et al. (2011) Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstract 29(15_suppl):1000.","DOI":"10.1200\/jco.2011.29.15_suppl.1000"},{"issue":"4","key":"4987_CR63","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3109\/0284186X.2012.707787","volume":"52","author":"TK Bergmann","year":"2012","unstructured":"Bergmann TK, Vach W, Feddersen S et al (2012) GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 52(4):871\u2013874 1\u20133","journal-title":"Acta Oncol"},{"issue":"50","key":"4987_CR64","doi-asserted-by":"publisher","first-page":"82244","DOI":"10.18632\/oncotarget.12545","volume":"7","author":"BP Schneider","year":"2016","unstructured":"Schneider BP, Lai D, Shen F et al (2016) Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 7(50):82244\u201382253","journal-title":"Oncotarget."},{"issue":"2","key":"4987_CR65","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/FPC.0000000000000318","volume":"28","author":"LE Sucheston-Campbell","year":"2018","unstructured":"Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE et al (2018) Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics 28(2):49\u201355","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"4987_CR66","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1172\/JCI96160","volume":"128","author":"AF Leblanc","year":"2018","unstructured":"Leblanc AF, Sprowl JA, Alberti P et al (2018) OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 128(2):816\u2013825","journal-title":"J Clin Invest"},{"issue":"29","key":"4987_CR67","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","volume":"25","author":"S Marsh","year":"2007","unstructured":"Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25(29):4528\u20134535","journal-title":"J Clin Oncol"},{"issue":"19","key":"4987_CR68","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1158\/1078-0432.CCR-15-2823","volume":"22","author":"DL Hertz","year":"2016","unstructured":"Hertz DL, Owzar K, Lessans S et al (2016) Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 22(19):4890\u20134900","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4987_CR69","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajhg.2016.05.008","volume":"99","author":"GM Lenk","year":"2016","unstructured":"Lenk GM, Szymanska K, Debska-Vielhaber G et al (2016) Biallelic mutations of VAC14 in pediatric-onset neurological disease. Am J Hum Genet 99(1):188\u2013194","journal-title":"Am J Hum Genet"},{"issue":"4","key":"4987_CR70","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hon.2337","volume":"35","author":"R Garcia-Sanz","year":"2017","unstructured":"Garcia-Sanz R, Corchete LA, Alcoceba M et al (2017) Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematol Oncol 35(4):746\u2013751","journal-title":"Hematol Oncol"},{"issue":"9","key":"4987_CR71","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 100(9):3063\u20133067","journal-title":"Blood."},{"issue":"4 Suppl 4","key":"4987_CR72","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","volume":"42","author":"KC Anderson","year":"2005","unstructured":"Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 42(4 Suppl 4):S3\u2013S8","journal-title":"Semin Hematol"},{"issue":"10","key":"4987_CR73","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ctrv.2014.10.001","volume":"40","author":"T Ng","year":"2014","unstructured":"Ng T, Chan M, Khor CC, Ho HK, Chan A (2014) The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. Cancer Treat Rev 40(10):1199\u20131214","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 1","key":"4987_CR74","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1097\/j.pain.0000000000001301","volume":"159","author":"AC Themistocleous","year":"2018","unstructured":"Themistocleous AC, Crombez G, Baskozos G, Bennett DL (2018) Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain. 159(Suppl 1):S31\u2013S42","journal-title":"Pain."},{"issue":"2","key":"4987_CR75","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1371\/journal.pmed.1000022","volume":"6","author":"J Little","year":"2009","unstructured":"Little J, Higgins JP, Ioannidis JP et al (2009) STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6(2):e22","journal-title":"PLoS Med"},{"issue":"9","key":"4987_CR76","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-10-2474","volume":"17","author":"A Backshall","year":"2011","unstructured":"Backshall A, Sharma R, Clarke SJ, Keun HC (2011) Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res: an official journal of the American Association for Cancer Research 17(9):3019\u20133028","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"4","key":"4987_CR77","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126(4):663\u2013676","journal-title":"Cell."},{"key":"4987_CR78","doi-asserted-by":"crossref","unstructured":"Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB (2019) Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res","DOI":"10.1158\/1078-0432.CCR-18-2152"},{"key":"4987_CR79","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jbi.2016.10.012","volume":"64","author":"EJ de Andres-Galiana","year":"2016","unstructured":"de Andres-Galiana EJ, Fernandez-Martinez JL, Sonis ST (2016) Sensitivity analysis of gene ranking methods in phenotype prediction. J Biomed Inform 64:255\u2013264","journal-title":"J Biomed Inform"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04987-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04987-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04987-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T17:40:34Z","timestamp":1664041234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04987-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4987"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04987-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"23 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This project was not specifically funded by any organization, but a couple of the investigators are generally funded by the National Institutes of Health\/National Cancer Institute (R01CA211887, R01CACA189947)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}